Quick Answer
NEOGENOMICS INC reported Net Income of -$108.03 million for fiscal year 2025.
NEOGENOMICS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$108.03M -37.2% |
-$78.73M +10.5% |
-$87.97M +39.0% |
-$144.25M -1628.2% |
-$8.35M -300.1% |
$4.17M -47.9% |
| Diluted EPS | — | — | — | — | — | — |
| Total Assets | $1.36B -17.0% |
$1.64B -2.6% |
$1.68B -3.4% |
$1.74B -6.9% |
$1.87B +89.2% |
$988.33M +39.3% |
| Cash and Equivalents | $159.62M -56.5% |
$367.01M +7.2% |
$342.49M +30.1% |
$263.18M -16.9% |
$316.83M +38.5% |
$228.71M +32.2% |
| Stockholders Equity | $836.56M -7.3% |
$902.34M -4.2% |
$941.54M -5.7% |
$998.02M -9.9% |
$1.11B +59.6% |
$694.29M +36.8% |
| R&D Expense | $37.08M +19.0% |
$31.16M +14.1% |
$27.31M -9.9% |
$30.33M +38.6% |
$21.87M +165.8% |
$8.23M -3.0% |
| Operating Income | -$115.88M -25.8% |
-$92.11M +14.5% |
-$107.74M +31.6% |
-$157.62M -32.7% |
-$118.75M -748.7% |
-$13.99M -207.6% |
| Gross Profit | $314.29M +8.3% |
$290.10M +18.6% |
$244.60M +30.2% |
$187.90M +0.4% |
$187.06M +0.6% |
$185.89M -5.6% |
| Shares Outstanding | 128.15M +0.0% |
128.15M +0.6% |
127.37M +0.4% |
126.91M +2.3% |
124.11M +10.7% |
112.08M +7.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$27.13M | -53.3% | +39.8% |
| Diluted EPS | September 30, 2016 | -$0.07 | — | +0.0% |
| Total Assets | September 30, 2025 | $1.37B | -16.2% | -1.4% |
| Cash and Equivalents | September 30, 2025 | $164.12M | -54.7% | +6.1% |
| Long-Term Debt | September 30, 2016 | $52.19M | — | -0.1% |
| Stockholders Equity | September 30, 2025 | $838.29M | -7.7% | -1.8% |
| R&D Expense | September 30, 2025 | $8.69M | +13.1% | -3.6% |
| Operating Income | September 30, 2025 | -$27.01M | -27.4% | +43.3% |
| Gross Profit | September 30, 2025 | $80.45M | +7.4% | +4.1% |
| Shares Outstanding | September 30, 2025 | 128.89M | +0.6% | +0.2% |
- NEOGENOMICS INC reported Net Income of -$108.03 million for fiscal year 2025.
- NEOGENOMICS INC showed a decrease of -37.2% in Net Income compared to the prior fiscal year.
- NEOGENOMICS INC reported Diluted EPS of $0.04 per share (loss) for fiscal year 2015.
- NEOGENOMICS INC showed a decrease of -300.0% in Diluted EPS compared to the prior fiscal year.
- NEOGENOMICS INC reported Total Assets of $1.36 billion for fiscal year 2025.
- NEOGENOMICS INC showed a decrease of -17.0% in Total Assets compared to the prior fiscal year.
- NEOGENOMICS INC reported Cash and Equivalents of $159.62 million for fiscal year 2025.
- NEOGENOMICS INC showed a decrease of -56.5% in Cash and Equivalents compared to the prior fiscal year.
- NEOGENOMICS INC reported Stockholders Equity of $836.56 million for fiscal year 2025.
- NEOGENOMICS INC showed a decrease of -7.3% in Stockholders Equity compared to the prior fiscal year.
- NEOGENOMICS INC reported R&D Expense of $37.08 million for fiscal year 2025.
- NEOGENOMICS INC showed an increase of +19.0% in R&D Expense compared to the prior fiscal year.
- NEOGENOMICS INC reported Operating Income of -$115.88 million for fiscal year 2025.
- NEOGENOMICS INC showed a decrease of -25.8% in Operating Income compared to the prior fiscal year.
- NEOGENOMICS INC reported Gross Profit of $314.29 million for fiscal year 2025.
- NEOGENOMICS INC showed an increase of +8.3% in Gross Profit compared to the prior fiscal year.
- NEOGENOMICS INC reported Shares Outstanding of 128.15 million shares for fiscal year 2025.
- NEOGENOMICS INC showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: